patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_494032 | REC_0004401 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 6.2 | 64 | female | 0 | 17 | 7 | 1 | pembrolizumab 200 mg q3w | 22.2 | false | MSS | 2026-03-15T05:35:57.934273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990953 | REC_0004402 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 18 | 5.1 | 90 | female | 2 | 65 | 5.9 | 0 | pembrolizumab 200 mg q3w | 22.6 | false | MSS | 2026-03-15T05:35:57.934501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779523 | REC_0004403 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 8.5 | 57 | male | 1 | 20 | 6 | 1 | pembrolizumab 200 mg q3w | 20.2 | false | MSS | 2026-03-15T05:35:57.934731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483481 | REC_0004404 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 5 | 8.8 | 62 | female | 1 | 11 | 5 | 5 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:57.934961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450067 | REC_0004405 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.8 | 80 | female | 1 | 54 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:57.935188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944220 | REC_0004406 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 10 | 10.9 | 70 | male | 2 | 27 | 9.6 | 1 | sotorasib 960 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:57.935425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659075 | REC_0004407 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 14.5 | 75 | female | 1 | 11 | 4.5 | 0 | entrectinib 600 mg daily | 22 | false | MSS | 2026-03-15T05:35:57.935656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562456 | REC_0004408 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.6 | 73 | female | 3 | 11 | 6.4 | 4 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.935924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739272 | REC_0004409 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 8.9 | 72 | female | 1 | 12 | 6.2 | 7 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:57.936246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172732 | REC_0004410 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 16.2 | 76 | female | 2 | 11 | 8.1 | 7 | entrectinib 600 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:57.936488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644433 | REC_0004411 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 1.5 | 71 | female | 2 | 22 | 4.1 | 6 | alectinib 600 mg BID | 14.2 | true | MSS | 2026-03-15T05:35:57.936721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641175 | REC_0004412 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.5 | 88 | female | 2 | 44 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:35:57.936959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460879 | REC_0004413 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 8 | 53 | female | 0 | 15 | 7.1 | 7 | alectinib 600 mg BID | 5.6 | true | MSS | 2026-03-15T05:35:57.937192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612849 | REC_0004414 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.5 | 63 | female | 1 | 60 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:57.937422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992670 | REC_0004415 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 18.6 | 81 | female | 2 | 15 | 5.8 | 0 | alectinib 600 mg BID | 20.6 | true | MSS | 2026-03-15T05:35:57.937659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300551 | REC_0004416 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.6 | 65 | female | 1 | 9 | 5.7 | 1 | sotorasib 960 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:35:57.937895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951581 | REC_0004417 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6 | 66 | female | 1 | 40 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:57.938125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286361 | REC_0004418 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 9.8 | 78 | female | 1 | 50 | 4.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:57.938351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743710 | REC_0004419 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 8.6 | 54 | male | 0 | 13 | 4.3 | 2 | pembrolizumab 200 mg q3w | 13.2 | true | MSS | 2026-03-15T05:35:57.938582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332666 | REC_0004420 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.2 | 79 | male | 1 | 10 | 5.5 | 7 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:57.938816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757260 | REC_0004421 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.1 | 58 | female | 0 | 9 | 5.7 | 4 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.939102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241558 | REC_0004422 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.6 | 69 | female | 1 | 66 | 7.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:57.939336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429297 | REC_0004423 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 17.6 | 58 | female | 0 | 17 | 5.5 | 2 | osimertinib 80 mg daily | 28.1 | false | MSS | 2026-03-15T05:35:57.939582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787364 | REC_0004424 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.2 | 61 | female | 0 | 9 | 6 | 5 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:57.939825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577141 | REC_0004425 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 17.4 | 69 | female | 1 | 11 | 6.2 | 6 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:57.940167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703402 | REC_0004426 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.1 | 68 | male | 0 | 67 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.4 | true | MSS | 2026-03-15T05:35:57.940440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957823 | REC_0004427 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 6.6 | 61 | male | 0 | 19 | 4.1 | 5 | alectinib 600 mg BID | 11.9 | true | MSS | 2026-03-15T05:35:57.940698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960106 | REC_0004428 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 9.2 | 61 | male | 0 | 14 | 6.6 | 6 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:57.940939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372774 | REC_0004429 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 13.6 | 85 | female | 3 | 8 | 8.2 | 3 | entrectinib 600 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:57.941188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939321 | REC_0004430 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 18 | 8.2 | 73 | female | 1 | 51 | 7.5 | 0 | pembrolizumab 200 mg q3w | 36.6 | false | MSS | 2026-03-15T05:35:57.941438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161385 | REC_0004431 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 13.6 | 79 | male | 1 | 14 | 7.3 | 1 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.941697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896930 | REC_0004432 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.5 | 65 | male | 1 | 56 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:35:57.941947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508870 | REC_0004433 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 18.8 | 79 | male | 1 | 26 | 6.6 | 7 | osimertinib 80 mg daily | 6.3 | false | MSI-H | 2026-03-15T05:35:57.942190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262529 | REC_0004434 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.6 | 71 | female | 1 | 30 | 5.6 | 1 | alectinib 600 mg BID | 24.9 | false | MSS | 2026-03-15T05:35:57.942562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_290247 | REC_0004435 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 13.1 | 51 | male | 0 | 18 | 5.6 | 3 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:57.942809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386998 | REC_0004436 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 12.2 | 83 | female | 2 | 22 | 4 | 0 | osimertinib 80 mg daily | 21.4 | true | MSI-H | 2026-03-15T05:35:57.943049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285213 | REC_0004437 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 6.6 | 58 | female | 0 | 4 | 5.3 | 5 | osimertinib 80 mg daily | 19.8 | true | MSS | 2026-03-15T05:35:57.943282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542172 | REC_0004438 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 6.6 | 70 | female | 0 | 72 | 3 | 4 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:57.943515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635691 | REC_0004439 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 14.6 | 63 | male | 0 | 10 | 6.5 | 3 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:57.943754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349707 | REC_0004440 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.3 | 77 | female | 2 | 10 | 4.5 | 10 | osimertinib 80 mg daily | 19.9 | false | MSS | 2026-03-15T05:35:57.943984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976273 | REC_0004441 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 13.8 | 80 | female | 2 | 13 | 7.6 | 4 | sotorasib 960 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:57.944372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931755 | REC_0004442 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 14.5 | 75 | female | 2 | 21 | 5.5 | 5 | sotorasib 960 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:57.944615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779580 | REC_0004443 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 14 | 12.4 | 70 | female | 2 | 11 | 6.6 | 0 | osimertinib 80 mg daily | 28.2 | true | MSI-H | 2026-03-15T05:35:57.944857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252799 | REC_0004444 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 6.3 | 61 | male | 0 | 14 | 4.7 | 5 | sotorasib 960 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:57.945093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481977 | REC_0004445 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 3.7 | 70 | female | 3 | 47 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 26.1 | false | MSS | 2026-03-15T05:35:57.945336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397769 | REC_0004446 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 11 | 68 | female | 0 | 14 | 6.7 | 0 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:57.945574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353673 | REC_0004447 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 9.1 | 66 | female | 0 | 19 | 4.2 | 8 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:57.945892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850729 | REC_0004448 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.8 | 56 | male | 0 | 30 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:57.946133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601638 | REC_0004449 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 11.4 | 68 | female | 1 | 16 | 6.2 | 7 | sotorasib 960 mg daily | 8 | true | MSS | 2026-03-15T05:35:57.946368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727839 | REC_0004450 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.6 | 82 | female | 1 | 9 | 6.2 | 6 | entrectinib 600 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:57.946599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598993 | REC_0004451 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 3.4 | 73 | female | 1 | 18 | 4.3 | 6 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:57.946828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805811 | REC_0004452 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.3 | 60 | female | 0 | 11 | 3.7 | 2 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:57.947065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614473 | REC_0004453 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.8 | 66 | female | 1 | 12 | 3.9 | 5 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.947297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456959 | REC_0004454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.9 | 67 | female | 1 | 14 | 3.3 | 6 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:57.947531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864584 | REC_0004455 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 13.7 | 79 | female | 2 | 15 | 6.3 | 1 | osimertinib 80 mg daily | 35.8 | false | MSS | 2026-03-15T05:35:57.947765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739906 | REC_0004456 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 7.9 | 62 | male | 1 | 16 | 4 | 1 | alectinib 600 mg BID | 27.1 | false | MSS | 2026-03-15T05:35:57.947996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743324 | REC_0004457 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 5.8 | 71 | female | 1 | 64 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.6 | true | MSS | 2026-03-15T05:35:57.948270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875104 | REC_0004458 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 14.2 | 67 | male | 1 | 0 | 7.6 | 7 | alectinib 600 mg BID | 11.4 | true | MSS | 2026-03-15T05:35:57.948511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954187 | REC_0004459 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 22.9 | 56 | male | 0 | 16 | 5.8 | 0 | alectinib 600 mg BID | 45.4 | false | MSS | 2026-03-15T05:35:57.948753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827183 | REC_0004460 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.8 | 62 | female | 0 | 41 | 4.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.7 | true | MSS | 2026-03-15T05:35:57.949035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478246 | REC_0004461 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 7.9 | 74 | female | 2 | 13 | 2 | 2 | sotorasib 960 mg daily | 25.2 | true | MSS | 2026-03-15T05:35:57.949274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414139 | REC_0004462 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.5 | 83 | female | 2 | 36 | 5.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:57.949508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304286 | REC_0004463 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 10 | 71 | female | 3 | 22 | 5.9 | 2 | alectinib 600 mg BID | 17.3 | true | MSI-H | 2026-03-15T05:35:57.949744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305907 | REC_0004464 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 13 | 86 | female | 0 | 9 | 6 | 2 | pembrolizumab 200 mg q3w | 21 | true | MSS | 2026-03-15T05:35:57.949978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929849 | REC_0004465 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.5 | 71 | female | 2 | 16 | 7 | 6 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:57.950208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945202 | REC_0004466 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 5.2 | 70 | female | 3 | 8 | 7.5 | 4 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:57.950432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103989 | REC_0004467 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 7.9 | 75 | female | 2 | 15 | 8.7 | 4 | alectinib 600 mg BID | 10.9 | true | MSS | 2026-03-15T05:35:57.950659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666486 | REC_0004468 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 20.9 | 75 | female | 2 | 16 | 4.4 | 7 | sotorasib 960 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:35:57.950894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742835 | REC_0004469 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.5 | 77 | female | 2 | 11 | 8.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:57.951122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533592 | REC_0004470 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14 | 55 | male | 0 | 12 | 7.4 | 6 | entrectinib 600 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:57.951357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467281 | REC_0004471 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 16 | 8.7 | 58 | female | 1 | 17 | 5.5 | 1 | pembrolizumab 200 mg q3w | 16.2 | false | MSS | 2026-03-15T05:35:57.951588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711778 | REC_0004472 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 3.6 | 70 | male | 2 | 8 | 7 | 3 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:57.951821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637373 | REC_0004473 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.8 | 75 | female | 2 | 8 | 6.5 | 1 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:57.952168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541651 | REC_0004474 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 5.3 | 82 | male | 2 | 16 | 5 | 2 | sotorasib 960 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.952414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432084 | REC_0004475 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 10.4 | 69 | female | 0 | 22 | 5.2 | 5 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:57.952662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805342 | REC_0004476 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.3 | 68 | female | 1 | 51 | 4.9 | 4 | pembrolizumab 200 mg q3w | 8.7 | true | MSS | 2026-03-15T05:35:57.952892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115057 | REC_0004477 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 17.2 | 82 | female | 1 | 14 | 7.5 | 8 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:57.953128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996033 | REC_0004478 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 13.9 | 70 | female | 1 | 13 | 6.9 | 2 | osimertinib 80 mg daily | 24.6 | false | MSI-H | 2026-03-15T05:35:57.953362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838146 | REC_0004479 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.9 | 60 | female | 0 | 47 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.5 | true | MSS | 2026-03-15T05:35:57.953593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580629 | REC_0004480 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.1 | 73 | female | 1 | 7 | 5.5 | 5 | alectinib 600 mg BID | 9.4 | true | MSI-H | 2026-03-15T05:35:57.953827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580431 | REC_0004481 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 4.2 | 69 | female | 1 | 14 | 5 | 7 | alectinib 600 mg BID | 13.8 | false | MSS | 2026-03-15T05:35:57.954054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695185 | REC_0004482 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 11.6 | 67 | female | 1 | 6 | 5.5 | 2 | osimertinib 80 mg daily | 23.7 | false | MSI-H | 2026-03-15T05:35:57.954287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302343 | REC_0004483 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 19 | 8.6 | 71 | female | 1 | 23 | 6.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 51 | false | MSS | 2026-03-15T05:35:57.954514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366765 | REC_0004484 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14 | 59 | female | 0 | 4 | 5.8 | 6 | osimertinib 80 mg daily | 9.7 | true | MSS | 2026-03-15T05:35:57.954751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153962 | REC_0004485 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 12.1 | 65 | female | 1 | 16 | 5.1 | 0 | sotorasib 960 mg daily | 39.7 | false | MSS | 2026-03-15T05:35:57.954983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386863 | REC_0004486 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.3 | 64 | male | 1 | 17 | 4.9 | 6 | entrectinib 600 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.955269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684991 | REC_0004487 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 3.7 | 67 | male | 0 | 84 | 5.4 | 1 | pembrolizumab 200 mg q3w | 12.8 | true | MSS | 2026-03-15T05:35:57.955509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494188 | REC_0004488 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 3.7 | 62 | female | 0 | 49 | 5.9 | 0 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:57.955742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748560 | REC_0004489 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 9.5 | 62 | male | 1 | 8 | 5.1 | 1 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:57.955975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249048 | REC_0004490 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 6.8 | 63 | male | 0 | 29 | 5 | 1 | osimertinib 80 mg daily | 26.8 | true | MSS | 2026-03-15T05:35:57.956318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978890 | REC_0004491 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11.2 | 70 | female | 3 | 14 | 5.8 | 1 | sotorasib 960 mg daily | 15.6 | false | MSI-H | 2026-03-15T05:35:57.956559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397428 | REC_0004492 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 15.9 | 57 | female | 1 | 0 | 4.2 | 6 | osimertinib 80 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:57.956799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232072 | REC_0004493 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.5 | 64 | male | 1 | 16 | 2.2 | 2 | sotorasib 960 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.957036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522445 | REC_0004494 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.3 | 68 | female | 1 | 38 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:57.957269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347239 | REC_0004495 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 23 | 12.3 | 64 | female | 0 | 23 | 5.2 | 0 | pembrolizumab 200 mg q3w | 22.7 | true | MSS | 2026-03-15T05:35:57.957508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789274 | REC_0004496 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 16.2 | 71 | male | 0 | 13 | 6.1 | 1 | alectinib 600 mg BID | 6.3 | true | MSI-H | 2026-03-15T05:35:57.957745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249833 | REC_0004497 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.4 | 71 | female | 1 | 25 | 5.9 | 2 | entrectinib 600 mg daily | 26.6 | false | MSS | 2026-03-15T05:35:57.957977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584290 | REC_0004498 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.6 | 61 | male | 0 | 66 | 3.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:35:57.958209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197170 | REC_0004499 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.3 | 72 | male | 0 | 13 | 4.7 | 2 | osimertinib 80 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:35:57.958500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207829 | REC_0004500 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 37 | 12.6 | 74 | female | 0 | 18 | 4.3 | 0 | alectinib 600 mg BID | 19.8 | true | MSS | 2026-03-15T05:35:57.958740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.